|
IL315833A
(en)
|
2010-08-02 |
2024-11-01 |
Regeneron Pharma |
Mice producing binding proteins containing VL regions
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
RS63571B9
(sr)
|
2013-09-13 |
2023-02-28 |
Beigene Switzerland Gmbh |
Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
|
|
MX377716B
(es)
|
2013-11-20 |
2025-03-11 |
Regeneron Pharma |
Moduladores de aplnr y usos de estos.
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI754319B
(zh)
*
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
ES2762640T3
(es)
|
2014-03-21 |
2020-05-25 |
Regeneron Pharma |
Proteínas VL de unión a antígeno que exhiben diferentes características de unión
|
|
BR112016021572A2
(pt)
|
2014-03-21 |
2017-10-03 |
Regeneron Pharma |
Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
|
|
US10544225B2
(en)
|
2014-07-03 |
2020-01-28 |
Beigene, Ltd. |
Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
|
|
CN106573052B
(zh)
|
2014-07-22 |
2021-04-06 |
中美冠科生物技术（太仓）有限公司 |
抗pd-1抗体
|
|
WO2016022630A1
(en)
|
2014-08-05 |
2016-02-11 |
Jiping Zha |
Anti-pd-l1 antibodies
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
CN107001461A
(zh)
|
2014-09-16 |
2017-08-01 |
瑞泽恩制药公司 |
抗胰高血糖素抗体及其使用方法
|
|
EP3699198B1
(en)
*
|
2014-11-17 |
2025-03-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
|
DK3223605T3
(da)
|
2014-11-24 |
2020-11-16 |
Regeneron Pharma |
Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks
|
|
HUE053995T2
(hu)
|
2014-12-05 |
2021-08-30 |
Memorial Sloan Kettering Cancer Center |
B-sejt-érési antigént célzó antitestek és alkalmazási eljárások
|
|
ES2966099T3
(es)
|
2014-12-05 |
2024-04-18 |
Memorial Sloan Kettering Cancer Center |
Receptores de antígeno quiméricos dirigidos al antígeno de maduración de células B y usos de los mismos
|
|
SG11201704550XA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
DK3277725T3
(da)
|
2015-03-30 |
2021-01-11 |
Regeneron Pharma |
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
|
|
AU2016255768B2
(en)
|
2015-04-29 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
|
EA039429B1
(ru)
*
|
2015-05-13 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения опухолей с применением биспецифического антитела cd3xcd20
|
|
CA2987641A1
(en)
|
2015-07-06 |
2017-01-12 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
KR101712638B1
(ko)
*
|
2015-08-19 |
2017-03-07 |
한국과학기술연구원 |
Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제
|
|
PT3353212T
(pt)
|
2015-09-23 |
2022-01-05 |
Regeneron Pharma |
Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TWI752920B
(zh)
|
2015-10-12 |
2022-01-21 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
EP3383913A4
(en)
|
2015-12-04 |
2019-10-30 |
Memorial Sloan-Kettering Cancer Center |
ANTIBODY AGAINST FC RECEPTOR LIKE 5 AND METHOD OF USE
|
|
HRP20231156T1
(hr)
|
2015-12-22 |
2024-01-05 |
Regeneron Pharmaceuticals, Inc. |
Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
|
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
|
SG10202010155YA
(en)
*
|
2016-04-20 |
2020-11-27 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
|
TW201803981A
(zh)
*
|
2016-04-20 |
2018-02-01 |
再生元醫藥公司 |
用於以使用增強表現基因座爲基礎製造抗體之組成物及方法
|
|
US11352446B2
(en)
|
2016-04-28 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
IL321475A
(en)
*
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
EP3470424B1
(en)
*
|
2016-06-08 |
2025-04-23 |
Shanghai Jiao Tong University School of Medicine |
Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
|
|
MY196006A
(en)
|
2016-06-14 |
2023-03-06 |
Regeneron Pharma |
Anti-C5 Antibodies and Uses Thereof
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
CN106191072A
(zh)
*
|
2016-08-04 |
2016-12-07 |
沈沭彤 |
重组人源嵌合GcFc基因片段及融合蛋白
|
|
AU2017313085B2
(en)
|
2016-08-19 |
2024-06-20 |
Beone Medicines I Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
|
MA46417A
(fr)
|
2016-09-23 |
2019-07-31 |
Regeneron Pharma |
Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
|
|
RS63660B1
(sr)
|
2016-09-23 |
2022-11-30 |
Regeneron Pharma |
Anti-muc16 (mucin 16) antitela
|
|
FI3538554T3
(fi)
|
2016-11-08 |
2025-09-24 |
Regeneron Pharma |
Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
BR112019011186A2
(pt)
|
2016-12-01 |
2019-10-08 |
Regeneron Pharmaceuticals, Inc. |
conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
|
|
CN110461847B
(zh)
|
2017-01-25 |
2022-06-07 |
百济神州有限公司 |
(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
|
|
CN110650974B
(zh)
|
2017-02-10 |
2024-04-19 |
瑞泽恩制药公司 |
用于免疫-pet成像的放射性标记的抗-lag3抗体
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
CN114989305A
(zh)
*
|
2017-03-31 |
2022-09-02 |
北京智仁美博生物科技有限公司 |
新型双特异性抗体及其用途
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
EA201992630A1
(ru)
|
2017-05-06 |
2020-04-29 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
|
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
BR112019025888A2
(pt)
|
2017-06-07 |
2020-06-30 |
Regeneron Pharmaceuticals, Inc. |
polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
|
|
WO2019001417A1
(en)
|
2017-06-26 |
2019-01-03 |
Beigene, Ltd. |
IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
|
|
US10806780B2
(en)
|
2017-06-28 |
2020-10-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
|
TW202348250A
(zh)
|
2017-07-24 |
2023-12-16 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
|
JP7304846B2
(ja)
|
2017-07-24 |
2023-07-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｃｄ８抗体およびその使用
|
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CN111148758B
(zh)
|
2017-09-29 |
2022-12-09 |
瑞泽恩制药公司 |
结合葡萄球菌属靶抗原和补体成分的双特异性抗原结合分子及其用途
|
|
WO2019090003A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
KR20200098528A
(ko)
|
2017-12-13 |
2020-08-20 |
리제너론 파아마슈티컬스, 인크. |
항-c5 항체 조합물 및 이의 용도
|
|
AU2018390811A1
(en)
|
2017-12-18 |
2020-07-02 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
|
|
CN109971720B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
靶向ErbB受体家族的嵌合抗原受体修饰T细胞及其用途
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US20190218285A1
(en)
*
|
2018-01-18 |
2019-07-18 |
Molecular Cloning Laboratories (MCLAB) LLC |
Long-Acting Therapeutic Fusion Proteins
|
|
CA3088194A1
(en)
|
2018-01-26 |
2019-08-01 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to influenza hemagglutinin
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210051929A1
(en)
|
2018-03-24 |
2021-02-25 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
|
CA3094400A1
(en)
|
2018-04-06 |
2019-10-10 |
Regeneron Pharmaceuticals, Inc. |
A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
|
|
EP3788075A1
(en)
|
2018-04-30 |
2021-03-10 |
Regeneron Pharmaceuticals, Inc. |
Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
|
|
MY206284A
(en)
|
2018-05-17 |
2024-12-06 |
Regeneron Pharma |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
MA52966A
(fr)
|
2018-06-19 |
2021-04-28 |
Regeneron Pharma |
Anticorps anti-facteur xii/xiia et leurs utilisations
|
|
TWI890661B
(zh)
|
2018-06-21 |
2025-07-21 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
SG11202101608XA
(en)
|
2018-08-23 |
2021-03-30 |
Regeneron Pharma |
Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
|
|
DK3844189T3
(da)
|
2018-08-31 |
2025-02-24 |
Regeneron Pharma |
Doseringsstrategi, der mindsker cytokinfrigivelsessyndrom for CD3/CD20-bispecifikke antistoffer
|
|
SG11202101037QA
(en)
|
2018-10-23 |
2021-02-25 |
Regeneron Pharma |
Anti-npr1 antibodies and uses thereof
|
|
CN112867732A
(zh)
|
2018-11-21 |
2021-05-28 |
瑞泽恩制药公司 |
抗葡萄球菌抗体和其用途
|
|
SG11202106658XA
(en)
|
2018-12-21 |
2021-07-29 |
Regeneron Pharma |
Rifamycin analogs and antibody-drug conjugates thereof
|
|
CN120157765A
(zh)
|
2019-02-01 |
2025-06-17 |
瑞泽恩制药公司 |
抗IL2受体γ抗原结合蛋白
|
|
EP3923978A1
(en)
|
2019-02-12 |
2021-12-22 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN114127112A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
|
|
AU2020224154B2
(en)
|
2019-02-21 |
2025-05-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2020172596A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and thereof
|
|
US11912767B2
(en)
|
2019-03-22 |
2024-02-27 |
Regeneron Pharmaceuticals, Inc. |
EGFR × CD28 multispecific antibodies
|
|
WO2020214963A1
(en)
*
|
2019-04-18 |
2020-10-22 |
Genentech, Inc. |
Antibody potency assay
|
|
SG11202111414RA
(en)
|
2019-04-24 |
2021-11-29 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
|
AU2020292283A1
(en)
|
2019-06-11 |
2021-12-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
|
|
CN114025802B
(zh)
|
2019-06-21 |
2024-04-23 |
瑞泽恩制药公司 |
结合psma和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
|
|
CN118453851A
(zh)
|
2019-06-21 |
2024-08-09 |
瑞泽恩制药公司 |
结合muc16和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
|
|
AU2020327000A1
(en)
|
2019-08-08 |
2022-03-31 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
WO2021030680A1
(en)
|
2019-08-15 |
2021-02-18 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
|
CN114340684B
(zh)
|
2019-09-16 |
2025-09-12 |
瑞泽恩制药公司 |
用于免疫pet成像的放射性标记的met结合蛋白
|
|
CN114761428A
(zh)
|
2019-10-28 |
2022-07-15 |
瑞泽恩制药公司 |
抗血凝素抗体及其使用方法
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
MX2022006714A
(es)
|
2019-12-06 |
2022-08-08 |
Regeneron Pharma |
Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.
|
|
US20210188934A1
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
JP2023509708A
(ja)
|
2020-01-03 |
2023-03-09 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
CA3164168A1
(en)
|
2020-01-08 |
2021-07-15 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
|
AU2021218675A1
(en)
|
2020-02-11 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-ACVR1 antibodies and uses thereof
|
|
CN111411079B
(zh)
*
|
2020-03-27 |
2025-12-12 |
北京时合生物科技有限公司 |
细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
|
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
|
JP2023525034A
(ja)
|
2020-05-08 |
2023-06-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
|
|
CN115667290A
(zh)
|
2020-05-12 |
2023-01-31 |
再生元制药公司 |
新型il10激动剂及其使用方法
|
|
US11999777B2
(en)
|
2020-06-03 |
2024-06-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
|
|
US11197910B1
(en)
*
|
2020-08-19 |
2021-12-14 |
Vitruviae LLC |
Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
|
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
PE20231657A1
(es)
|
2020-09-15 |
2023-10-17 |
Regeneron Pharma |
Uso de agonistas de lepr para el dolor
|
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
JP2023543152A
(ja)
|
2020-09-18 |
2023-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
|
|
EP4222171A1
(en)
|
2020-10-02 |
2023-08-09 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
|
IL301702A
(en)
|
2020-10-22 |
2023-05-01 |
Regeneron Pharma |
Anti-FGFR2 antibodies and methods of using them
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
CA3202629A1
(en)
|
2020-12-18 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to npr1 agonists
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
HRP20250696T1
(hr)
|
2021-01-28 |
2025-08-01 |
Regeneron Pharmaceuticals, Inc. |
Sastavi i postupci za liječenje sindroma oslobađanja citokina
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
MX2023012974A
(es)
|
2021-05-04 |
2023-11-15 |
Regeneron Pharma |
Agonistas multiespecificos de receptores del fgf21 y sus usos.
|
|
AU2022274888A1
(en)
|
2021-05-11 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-tmprss6 antibodies and uses thereof
|
|
CA3226924A1
(en)
|
2021-07-19 |
2023-01-26 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
CN118451097A
(zh)
|
2021-08-16 |
2024-08-06 |
再生元制药公司 |
新型il27受体激动剂及其使用方法
|
|
WO2023081434A2
(en)
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
|
TW202334223A
(zh)
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Ｃｄ２０－ｐｄ１結合分子及其使用方法
|
|
CA3238750A1
(en)
|
2021-11-24 |
2023-06-01 |
Ella Ioffe |
Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
|
|
US20230250170A1
(en)
|
2021-12-06 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
|
KR20240130137A
(ko)
|
2022-01-07 |
2024-08-28 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법
|
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
|
US20230303719A1
(en)
|
2022-03-03 |
2023-09-28 |
Yale University |
Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
|
|
CN119677534A
(zh)
|
2022-03-17 |
2025-03-21 |
瑞泽恩制药公司 |
使用双特异性抗muc16×抗cd3抗体单独或与抗pd-1抗体组合来治疗复发性上皮样肉瘤的方法
|
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
|
AU2023254191A1
(en)
|
2022-04-11 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
EP4518973A1
(en)
|
2022-05-03 |
2025-03-12 |
RegenxBio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
JP2025516596A
(ja)
|
2022-05-11 |
2025-05-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性結合分子プロタンパク質及びその使用
|
|
AU2023272836A1
(en)
|
2022-05-16 |
2024-12-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
|
CN119451979A
(zh)
|
2022-05-27 |
2025-02-14 |
再生元制药公司 |
白细胞介素-2蛋白质原及其用途
|
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
AU2023285085A1
(en)
|
2022-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
|
JP2025525792A
(ja)
|
2022-07-29 |
2025-08-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
トランスフェリン受容体１に対して再標的化されるウイルス粒子
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
|
|
CN120265655A
(zh)
|
2022-07-29 |
2025-07-04 |
瑞泽恩制药公司 |
抗tfr：有效载荷融合物及其使用方法
|
|
IL318426A
(en)
|
2022-08-02 |
2025-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
|
|
AU2023325400A1
(en)
|
2022-08-18 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
EP4598634A1
(en)
|
2022-10-03 |
2025-08-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
|
|
JP2025533939A
(ja)
|
2022-10-10 |
2025-10-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
固形臓器移植を必要とする対象における同種抗体レベルを低減する方法
|
|
AU2023367039A1
(en)
|
2022-10-25 |
2025-05-15 |
Ablexis, Llc |
Anti-cd3 antibodies
|
|
US20240150474A1
(en)
|
2022-10-27 |
2024-05-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
JP2025539938A
(ja)
|
2022-11-14 |
2025-12-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｆｇｆｒ３抗体および抗原結合断片ならびにそれらの使用方法
|
|
WO2024107731A2
(en)
|
2022-11-14 |
2024-05-23 |
Ablexis, Llc |
Anti-pd-l1 antibodies
|
|
JP2025538220A
(ja)
|
2022-11-14 |
2025-11-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
|
|
CN120712281A
(zh)
|
2022-12-16 |
2025-09-26 |
瑞泽恩制药公司 |
结合到aav颗粒的抗原结合分子和用途
|
|
CN120380024A
(zh)
|
2022-12-21 |
2025-07-25 |
建新公司 |
抗pd-1×4-1bb结合蛋白
|
|
US20240252601A1
(en)
|
2022-12-23 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
US20240270836A1
(en)
|
2023-01-13 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
EP4649092A1
(en)
|
2023-01-13 |
2025-11-19 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
CN120677178A
(zh)
|
2023-02-13 |
2025-09-19 |
瑞泽恩制药公司 |
用抗人cacng1抗体治疗肌肉相关病症
|
|
AR131856A1
(es)
|
2023-02-16 |
2025-05-07 |
Sanofi Sa |
Proteínas de unión a cd40
|
|
WO2024173830A2
(en)
|
2023-02-17 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
WO2024173876A1
(en)
|
2023-02-17 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
IL322890A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
|
|
IL322940A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multivalent anti-spike protein binding molecules and their uses
|
|
US20240287162A1
(en)
|
2023-02-28 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
Multivalent anti-spike protein binding molecules and uses thereof
|
|
CN121039163A
(zh)
|
2023-05-02 |
2025-11-28 |
瑞泽恩制药公司 |
抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
|
|
US20240400687A1
(en)
|
2023-05-10 |
2024-12-05 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2024238415A1
(en)
|
2023-05-12 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
WO2024258785A1
(en)
|
2023-06-11 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
WO2024259206A1
(en)
|
2023-06-16 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
|
|
TW202519559A
(zh)
|
2023-07-10 |
2025-05-16 |
美商再生元醫藥公司 |
雙特異性PD-L1xCD28抗體及其使用方法
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
US20250043017A1
(en)
|
2023-07-10 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2025019789A1
(en)
|
2023-07-19 |
2025-01-23 |
Regeneron Pharmaceuticals, Inc. |
ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025029657A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
WO2025030041A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025030044A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025049591A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-cxcr4 antibodies and uses thereof
|
|
WO2025080540A1
(en)
|
2023-10-09 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine
|
|
US20250154487A1
(en)
|
2023-11-10 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Engineered alpha klotho polypeptides and uses thereof
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
WO2025117869A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent ovarian cancer and endometrial cancer with bispecific anti-muc16 x anti-cd28 antibodies in combination with anti-pd-1 antibodies or bispecific anti-muc16 x anti-cd3 antibodies
|
|
US20250179137A1
(en)
|
2023-12-05 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025128652A1
(en)
|
2023-12-12 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025171124A1
(en)
|
2024-02-07 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
US20250277048A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250297006A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025240287A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
|
|
WO2025244973A1
(en)
|
2024-05-20 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255480A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025255508A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Engineered alpha klotho polypeptides and uses thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
WO2025259718A2
(en)
|
2024-06-11 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|